O-Methylviridicatin
(Synonyms: O-甲基纯绿青霉素,AIDS-089094,3-methoxy-4-phenyl-Carbostyril,Viridicatin methyl ester) 目录号 : GC14784
An inhibitor of TNF-α-induced HIV replication
Cas No.:6152-57-4
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
IC50: 2.5 μM: inhibits virus production in OM-10.1 cells (HL-60 promyelocytes infected with HIV-1) treated with TNF-α.
5 μM: blocks activation of the HIV long terminal repeat by TNF-α in HeLa cells
O-Methylviridicatin, a natural derivative of the alkaloid mycotoxin viridicatin, is produced by several species in the genus, Penicillium. It is demonstrated that O-Methylviridicatin, as an inhibitor, blocks the tumor necrosis factor alpha (TNFα)-induced replication of human immunodeficiency virus (HIV). TNFα increases the binding of the cellular transcription factor NF-κB to the HIV long terminal repeat (LTR), which directly triggers transcription of the latent provirus.
In vitro: O-Methylviridicatin had an inhibitory effect on the TNFα-triggered replication of HIV LTR in HeLa cells. In addition, O-Methylviridicatin dose-dependently dampened virus production in the OM-10.1 cell line, which was measured by the output of p24 core antigen into the culture medium. It was demonstrated that the suppressive effect of O-Methylviridicatin was not reversed even if the concentration of TNFα was increased 10-fold [1].
In vivo: Up to now, in vitro study of O-Methylviridicatin is still in the development stage.
Reference:
[1]. Heguy, A., Cai, P., Meyn, P., Houck, D., Russo, S., & Michitsch, R. et al. Isolation and Characterization of the Fungal Metabolite 3-O-Methylviridicatin as an Inhibitor of Tumour Necrosis Factor-Induced Human Immunodeficiency Virus Replication. Antiviral Chemistry and Chemotherapy. 1998; 9(2): 149-155.
| Cas No. | 6152-57-4 | SDF | |
| 别名 | O-甲基纯绿青霉素,AIDS-089094,3-methoxy-4-phenyl-Carbostyril,Viridicatin methyl ester | ||
| 化学名 | 3-methoxy-4-phenyl-2(1H)-quinolinone | ||
| Canonical SMILES | O=C1NC2=C(C=CC=C2)C(C3=CC=CC=C3)=C1OC | ||
| 分子式 | C16H13NO2 | 分子量 | 251.3 |
| 溶解度 | Soluble in DMSO | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 3.9793 mL | 19.8965 mL | 39.7931 mL |
| 5 mM | 0.7959 mL | 3.9793 mL | 7.9586 mL |
| 10 mM | 0.3979 mL | 1.9897 mL | 3.9793 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。